Today, Intra-Cellular Therapies Inc (NASDAQ: ITCI) Takes Center Stage

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

The company is listed on the NASDAQ and operates within the Drug Manufacturers – Specialty & Generic industry segment. At the end of the last regular session, the stock closed at $68.57 and fluctuated between $70.59 as its day high and $68.35 as its day low. The current market capitalization of Intra-Cellular Therapies Inc is $6.60B. A total of 1.16 million shares were traded on the day, compared to an average of 829.70K shares.

Insider Activity

Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, ITCI has seen 2 BUY and 2 SELL insider trades, representing the acquisition of 50,000 and the disposition of 50,000 shares. Over the last 12 months, there were 37 BUYs and 60 SELLs from insiders. Insiders purchased 590,812 shares during that period but sold 657,071.

In the most recent transaction, Mates Sharon sold 33,885 shares of ITCI for 67.07 per share on Feb 02. After the transaction, the Chairman, President & CEO now owns 1,050,309 company shares. In a previous transaction on Feb 02, Neumann Mark sold 11,860 shares at 67.15 per share. ITCI shares that EVP, Chief Commercial Officer owns now total 29,700.

Among the insiders who sold shares, Halstead Michael disposed of 11,860 shares on Feb 02 at a per-share price of $66.42. This resulted in the EVP and General Counsel holding 0 shares of ITCI after the transaction. In another insider transaction, Hineline Lawrence J. sold 11,183 shares at $66.62 per share on Feb 02. Company shares held by the SVP of Finance, CFO now total 0.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for ITCI in the last 3 months, the mean price target is $81.77 with high estimates of $101.00 and low estimates of $59.00. In terms of 52-week highs and lows, ITCI has a high of $74.17 and a low of $42.01.

As of this writing, ITCI has an earnings estimate of $Iteris, Inc. per share for the current quarter. EPS was calculated based on a consensus of Intra-Cellular Therapies Inc. estimates, with a high estimate of $Itron, Inc. per share and a lower estimate of $FTC Solar, Inc..

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ITCI’s latest balance sheet shows that the firm has $412.33M in Cash & Short Term Investments as of fiscal 2021. There were $25.41M in debt and $53.36M in liabilities at the time. Its Book Value Per Share was $6.24, while its Total Shareholder’s Equity was $417.89M.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ITCI is Buy with a score of 4.60.

Most Popular

Related Posts